The Oncology Institute(US:TOI) Globenewswire·2025-11-13 21:05Core Insights - The Oncology Institute, Inc. (TOI) reported strong financial results for Q3 2025, with consolidated revenue of $136.6 million, a 36.7% increase from $99.9 million in Q3 2024, and a net loss of $16.5 million compared to a net loss of $16.1 million in the prior year [3][4][20] - The company updated its full-year 2025 guidance, raising revenue expectations to between $495 million and $505 million, while Adjusted EBITDA guidance was adjusted to a loss of $11 million to $13 million [3][4] - TOI's fee-for-service revenue grew by 13% year-over-year, driven by organic growth in Florida and Oregon, and the retail pharmacy and dispensary segment set records with $75.9 million in revenue [4][5] Financial Performance - Consolidated revenue for Q3 2025 was $136.6 million, up from $99.9 million in Q3 2024, while gross profit increased to $18.9 million, a 31.7% rise [4][20] - The net loss for Q3 2025 was $16.5 million, slightly higher than the $16.1 million loss in Q3 2024, with basic and diluted loss per share improving to $(0.14) from $(0.18) [4][20] - Adjusted EBITDA for Q3 2025 was $(3.5) million, an improvement from $(8.2) million in Q3 2024 [4][20] Operational Highlights - The company signed several new in-network MSO providers in Florida and opened a new pharmacy location in the state [4][5] - TOI welcomed Kristin England as the new Chief Administrative Officer, focusing on enterprise operations and technology strategy [4][5] - The company reported a total of 80 clinics and 22 markets, maintaining the number of lives under value-based contracts at approximately 1.9 million [4][17] Guidance and Outlook - TOI expects Adjusted EBITDA of approximately $0 to $2 million in Q4 2025, reflecting a positive outlook for the remainder of the year [3][4] - The updated guidance for 2025 reflects the company's confidence in achieving revenue and profitability growth, despite potential risks in the operating environment [3][4]